News

A new study by researchers at Rice University in Houston used computer simulations to explore the beginnings of the molecular process that marks the start of Alzheimer’s disease, which is triggered by the aggregation of a common protein called amyloid beta. The Rice investigators are the first to model the energy…

Researchers have successfully used a viral transport mechanism to deliver a gene to the brain of mice that prevented the development of Alzheimer’s disease (AD). The results could have a profound impact on the future of gene therapy in treating Alzheimer’s. These were the findings from a study conducted by researchers…

According to a new study, people who have brain deposits of another faulty protein called TDP-43, in addition to amyloid-beta and tau aggregates, have a much higher risk of developing Alzheimer’s disease than those having only plaques and tangles. The study, “TDP-43 stage, mixed pathologies, and clinical…

Researchers have identified the factor at the end of a molecular chain of events killing nerve cells which have been exposed to damage from disease processes such as stroke and possibly Alzheimer’s or a wide variety of other injuries. The study, “A nuclease that mediates cell death induced by DNA damage…

A recent research study conducted at the University of Eastern Finland has found that psychotropic drug use is more common than previously thought among Alzheimer’s disease (AD) patients who were diagnosed at 90 years old or older, in comparison to those who were diagnosed at younger age. The…

Recombinetics has just announced that the National Institute on Aging, part of the National Institutes of Health (NIH), has awarded the company with a $358,338 Phase 1 Small Business Innovative Research (SBIR) grant to create a genetically accurate swine model of Alzheimer’s disease (AD). Recombinetics is a biotech…

Immunotherapy for Alzheimer’s disease may not provide a clinical benefit in patients that also developed vascular cognitive impairment and dementia (VCID), another form of dementia, according to a new study. The study, “Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity,”…

Larry Altstiel, MD, PhD, chief medical officer of vTv Therapeutics, will speak today on the panel “Novel Approaches to Alzheimer’s Disease,” during the Neuro Advance Boston conference hosted by Harvard Medical School. Altstiel will detail the mechanisms of action of azeliragon, vTv Therapeutics’ investigative treatment for mild Alzheimer’s disease…

The Alzheimer’s Drug Discovery Foundation (ADDF) announced that a Georgetown University Medical Center researcher has been awarded a $2.1 million grant to conduct a Phase 2 clinical trial of low-dose nilotinib (Tasigna, a cancer therapy) in patients with Alzheimer’s disease. The grant was awarded as part of the ADDF’s…

The number of clinical trials evaluating possible treatments for Alzheimer’s disease is on the increase, according to a recent analysis conducted by ResearchersAgainstAlzheimer’s (RA2), a global network of Alzheimer’s researchers that is part of a non-profit organization promoting the study and treatment of this disease, called UsAgainstAlzheimer’s. The…